2-Hydroxytetracos-9-enoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-Hydroxytetracos-9-enoic acid
• 英文别名: 2-hydroxytetracos-9-enoic acid
• 化学式: C₂₄H₄₆O₃
• 分子量: 382.6
• InChiKey: CIEDZDGIAAZVLQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.8
• 重原子数：
  27
• 可旋转键数：
  21
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• BIOPASSIVATING MEMBRANE STABILIZATION BY MEANS OF NITROCARBOXYLIC ACID-CONTAINING PHOSPHOLIPIDS IN PREPARATIONS AND COATINGS
  申请人：Dietz Ulrich

  公开号：US20140099354A1

  公开（公告）日：2014-04-10

  The present invention relates to nitro-carboxylic acid (s)-containing phospholipids, to be used for coating of medical devices such as stents, catheter balloons, wound pads or surgical suture material and for bio-passivating compositions, such as rinses, waterproofing solutions, coating solutions, cryoprotection solutions, cold preservation media, lyoprotection solutions, contrast media solutions, preservation and reperfusion solutions containing these compounds as well as preparing solutions thereof and coating medical devices as well as their uses.

  本发明涉及一种含硝基羧酸（s）的磷脂，用于涂覆医疗器械，如支架、导管球囊、伤口垫或外科缝合材料，以及用于生物钝化组合物，如漱口液、防水溶液、涂层溶液、冷冻保护溶液、冷藏介质、冻干保护溶液、造影介质溶液、含有这些化合物的保存和再灌注溶液，以及制备这些溶液和涂覆医疗器械以及它们的用途。
• COMPOSITION CONTAINING REDUCED COENZYME Q10, AND MANUFACTURING AND STABILISING METHODS THEREFOR
  申请人：Yamaguchi Takao

  公开号：US20130142767A1

  公开（公告）日：2013-06-06

  The present invention relates to a method of producing reduced coenzyme Q10, including reducing oxidized coenzyme Q10 using a reducing agent in terpenes that can highly dissolve oxidized coenzyme Q10 and reduced coenzyme Q10 in the co-existence of at least one kind of additive selected from the group consisting of alcohols, water, a surfactant and diacylglycerol. In addition, the present invention relates to a composition comprising terpenes, a reducing agent, reduced coenzyme Q10 and at least one kind selected from the group consisting of alcohols, water, a surfactant and diacylglycerol, and a method of stabilizing reduced coenzyme Q10 comprising preparing the composition.

  本发明涉及一种生产还原辅酶Q10的方法，包括使用一种在萜烯中高度溶解氧化辅酶Q10和还原辅酶Q10的还原剂，同时存在至少一种来自醇类、水、表面活性剂和二酰基甘油组的添加剂。此外，本发明涉及一种组合物，包括萜烯、还原剂、还原辅酶Q10和至少一种来自醇类、水、表面活性剂和二酰基甘油组的选择性添加剂，以及一种稳定还原辅酶Q10的方法，包括制备该组合物。
• HYDROXY CERAMIDES AND ANALOGS THEREOF AND THEIR USE FOR PREVENTING OR TREATING CANCER
  申请人：Szulc Zdzislaw M.

  公开号：US20120108667A1

  公开（公告）日：2012-05-03

  Disclosed herein are compounds, compositions, methods of treatment and synthetic methods for making compounds related to Ceramides and the use of Ceramides.

  本文披露了与鞘磷脂相关的化合物、组合物、治疗方法和合成方法以及鞘磷脂的使用。
• Bioavailability and improved delivery of alkaline pharmaceutical drugs
  申请人：——

  公开号：US20040214215A1

  公开（公告）日：2004-10-28

  Embodiments of the invention relate to a composition, a process of making the composition, and to the use of the composition. The compositions include a molecular complex formed between an alkaline pharmaceutical drug and at least one selected from a hydroxyacid, a polyhydroxy acid, a related acid, a lactone, or combinations thereof. The compositions provide improved bioavailability and improved delivery of the drug into the cutaneous tissues.

  本发明实施例涉及一种组合物、制备该组合物的过程以及使用该组合物。该组合物包括碱性药物和至少一种选择自羟酸、多羟酸、相关酸、内酯或其组合物的分子复合物。该组合物提供了改善的生物利用度和将药物输送至皮肤组织的改善输送。
• Aspartoacylase gene, protein, and methods of screening for mutations associated with Canavan disease
  申请人：Miami Children's Hospital Research Inst.

  公开号：US20030017473A1

  公开（公告）日：2003-01-23

  Canavan disease, an autosomal recessive leukodystrophy, is caused by deficiency of aspartoacylase and accumulation of N-acetylaspartic acid in brain. Human aspartoacylase (ASP) cDNA spanning 1,435 bp has been cloned and expressed in E. coli. A base change, a854>c, has been found in 85% of the 34 Canavan alleles tested so far, which results in a missense glu285>ala mutation that is predicted to be part of the catalytic domain of aspartoacylase. The invention therefore provides nucleic acid sequences, genes, polypeptides, antibodies, vectors containing the gene, host cells transformed with vectors containing the gene, animal models for the disease, methods for expressing the polypeptide, genetic screening methods and kits, diagnostic methods and kits, methods of treating Canavan disease and methods of genetic therapy for the disease.

  Canavan病是一种常染色体隐性遗传的白质脑病，由于天冬氨酸乙酰化酶的缺乏和N-乙酰天冬氨酸在大脑中的积累而引起。人类天冬氨酸乙酰化酶（ASP）cDNA跨越1435个碱基被克隆并在大肠杆菌中表达。迄今已经测试了34个Canavan等位基因中的85％，发现一个a854>c的碱基变化，导致一个预测为天冬氨酸乙酰化酶催化结构域的错义glu285>ala突变。因此，本发明提供了核酸序列、基因、多肽、抗体、含有该基因的载体、转化有该基因载体的宿主细胞、用于该疾病的动物模型、表达多肽的方法、遗传筛查方法和试剂盒、诊断方法和试剂盒、治疗Canavan病的方法以及该疾病的基因治疗方法。